This company listing is no longer active
5D8 Stock Overview
DEINOVE SA, a biotechnology company, discovers, develops, and produces compounds from microbials for the health, nutrition, and cosmetics industries worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Deinove SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.018 |
52 Week High | €0.31 |
52 Week Low | €0.0001 |
Beta | 0.78 |
1 Month Change | 0% |
3 Month Change | -11.59% |
1 Year Change | -93.51% |
3 Year Change | -97.48% |
5 Year Change | -99.50% |
Change since IPO | -99.77% |
Recent News & Updates
Recent updates
Shareholder Returns
5D8 | DE Chemicals | DE Market | |
---|---|---|---|
7D | 0% | -1.4% | -2.0% |
1Y | -93.5% | -1.2% | -0.3% |
Return vs Industry: 5D8 underperformed the German Chemicals industry which returned -10.6% over the past year.
Return vs Market: 5D8 underperformed the German Market which returned -9% over the past year.
Price Volatility
5D8 volatility | |
---|---|
5D8 Average Weekly Movement | n/a |
Chemicals Industry Average Movement | 4.1% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5D8's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 5D8's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 44 | Alexis Rideau | www.deinove.com |
DEINOVE SA, a biotechnology company, discovers, develops, and produces compounds from microbials for the health, nutrition, and cosmetics industries worldwide. The company’s pipeline includes DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers Dual-Acting Small Molecule Antibiotics, a class of dual activity antibiotics that develops a new class of 2-in-1 molecules whose structure results from the combination of two active antibiotic moieties.
Deinove SA Fundamentals Summary
5D8 fundamental statistics | |
---|---|
Market cap | €843.07k |
Earnings (TTM) | -€7.37m |
Revenue (TTM) | €241.00k |
3.5x
P/S Ratio-0.1x
P/E RatioIs 5D8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
5D8 income statement (TTM) | |
---|---|
Revenue | €241.00k |
Cost of Revenue | €3.91m |
Gross Profit | -€3.67m |
Other Expenses | €3.71m |
Earnings | -€7.37m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.23 |
Gross Margin | -1,521.58% |
Net Profit Margin | -3,058.92% |
Debt/Equity Ratio | -127.0% |
How did 5D8 perform over the long term?
See historical performance and comparison